M. Brawner Floyd

A quantitative analysis of kinase inhibitor selectivity

Mazen W. Karaman, Sanna Herrgård, Daniel K. Treiber et al. · Nature Biotechnology · 2008 · 2.4K citations

Drug Target, Signal Transduction, Medicine +6

A small molecule–kinase interaction map for clinical kinase inhibitors

Miles A. Fabian, William Biggs, Daniel K. Treiber et al. · Nature Biotechnology · 2005 · 1.9K citations · Full text

Molecular Docking, Drug Target, Clinical Kinase Inhibitors +4

Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

Sridhar K. Rabindran, Carolyn Discafani, Edward Rosfjord et al. · Cancer Research · 2004 · 628 citations · Full text

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

Todd A. Carter, Lisa Wodicka, Neil P. Shah et al. · Proceedings of the National Academy of Sciences · 2005 · 554 citations · Full text

Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity

Hwei‐Ru Tsou, Elsebe G. Overbeek-Klumpers, William Hallett et al. · Journal of Medicinal Chemistry · 2005 · 294 citations · Full text

Medicinal Chemistry, Biochemistry, Safer Cyclization Step +13